Department of Physical Medicine and Rehabilitation, Marmara University School of Medicine, Istanbul, Turkey.
Gynecol Endocrinol. 2011 Dec;27(12):1033-6. doi: 10.3109/09513590.2011.579657. Epub 2011 Jun 1.
To evaluate the effect of risedronate treatment on osteoprotegerin (OPG), C-terminal cross-linking telopeptide of type 1 collagen (CTX), osteocalcin (OC), and deoxypyridinoline (DPD).
Eighty postmenopausal osteoporotic patients were randomized into two groups. In first group, patients received 35?mg of risedronate once a week and calcium with vitamin D per day. In second group, patients received only calcium with vitamin D per day. Bone turnover markers were measured at baseline, 1st, 3rd and 6th month.
OPG levels were significantly reduced at 1st and 6th month of treatment in both groups, but no statistically significant difference was detected between groups. In the group treated with risedronate, difference in CTX level was observed at 3rd month of treatment, while a difference in DPD and OC levels were observed at 6th month of treatment. The baseline OPG levels correlated with age, menopause duration, and CTX levels. There was no correlation between OPG levels and the levels of the other markers during treatment.
The present study showed that using risedronate in treatment of postmenopausal osteoporosis causes no specific changes in OPG levels; therefore, in contrast to some of the studies in the literature OPG may not be useful marker in monitoring of bisphosphonate.
评估利塞膦酸钠治疗对骨保护素（OPG）、I 型胶原 C 端交联肽（CTX）、骨钙素（OC）和脱氧吡啶啉（DPD）的影响。
将 80 例绝经后骨质疏松症患者随机分为两组。第一组患者每周接受 35mg 利塞膦酸钠和每日钙剂加维生素 D 治疗。第二组患者仅接受每日钙剂加维生素 D 治疗。在基线、第 1、3 和 6 个月测量骨转换标志物。
两组患者在治疗第 1 和第 6 个月时 OPG 水平均显著降低，但组间无统计学差异。在利塞膦酸钠治疗组中，CTX 水平在治疗第 3 个月时出现差异，而 DPD 和 OC 水平在治疗第 6 个月时出现差异。OPG 水平与年龄、绝经时间和 CTX 水平相关。在治疗期间，OPG 水平与其他标志物的水平之间无相关性。
本研究表明，在绝经后骨质疏松症的治疗中使用利塞膦酸钠不会引起 OPG 水平的特定变化；因此，与文献中的一些研究不同，OPG 可能不是监测双膦酸盐的有用标志物。
